Stay updated with breaking news from Research Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Today in Washington ------------------------------------------------------------- This Diary is filed daily. ** Indicates new events -------------------------------------------------------------
April 1 (Reuters) - For other diaries, please see: Top Economic Events Emerging Markets Economic Events Government Debt Auctions Political and General News... | 08:01pm
A new oral phosphodiesterase-4 (PDE4) inhibitor achieved impressive rates of complete or near-complete skin clearance in a phase 2 study that also found the drug was well tolerated.
Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.
Share this article Share this article SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. "I am pleased to present the topline results from the ADVISE Phase 2 trial which support the rationale for etrasimod as a potentia...